Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1401-1410 of 1772 for

Edit search filters
  1. Database of All Patients with Peritoneal Surface Malignancies Treated at Mayo Clinic

    Rochester, MN

  2. Kinetics Of Troponin And BNP In Breast Cancer Chemotherapy With Adriamycin And Trastuzumab

    Jacksonville, FL

  3. Risk-Based Classification System Of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Rochester, MN

  4. A Study To Evaluate Immune Markers In Patients With Renal Cell Cancer

    Rochester, MN

  5. Financial Difficulty In Patients With Blood Cancer

    Scottsdale/Phoenix, AZ

  6. Circulating Nucleic Acid Based Biomarkers For Early Detection Of Hepatocellular Carcinoma (HCC)

    Jacksonville, FL

  7. Tele-Medicine In An Advanced Prostate Cancer Clinic

    Rochester, MN

  8. A Study to Evaluate Brain Natriuretic Peptides for the Avoidance of Treatment-Related Heart Failure in Breast Cancer Survivors

    Rochester, MN

  9. Risk Factors Associated with Clustered Plasma Cell Dyscrasias in Minnesota

    Rochester, MN

  10. Plasma Proneurotensin As A Predictive Biomarker For Breast Cancer In Genetically Predisposed Patients

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer